EnsoData is an artificial intelligence company focused on automating waveform analysis to diagnose, monitor, and manage non-malignant, acute, and chronic debilitating diseases. Their AI software unlocks the clinical data within waveforms collected across various timescales, addressing conditions such as heart rhythm irregularities, sleep disordered breathing, and more.

The company's flagship product, EnsoSleep, uses AI to significantly reduce the time needed for scoring sleep studies, improving efficiency and accuracy for sleep professionals. EnsoData's solutions support the 80% of the obstructive sleep apnea (OSA) patient population who remain undiagnosed, aiming to connect sleep disorder diagnosis to therapy. Their offerings include FDA-cleared software as medical devices (SaMD) such as EnsoSleep PPG for Home Sleep Testing, AI Scoring for polysomnography (PSG) and home sleep apnea tests (HSAT), and remote physiological monitoring (RPM).

EnsoData values collaboration with healthcare providers, offering one of the world's largest sleep study databases for free to researchers and device manufacturers to accelerate AI's impact in healthcare. The company emphasizes a hospitable culture centered on diversity, equity, and inclusion, as well as community involvement and employee well-being.